1Fareed J, Hoppensteadt DA. Pharmacology of the low-molecular-weight heparins. Semin Thromb Hemost, 1996,22(suppl 2): 13-18.
2Jonas S, Sugimori M, Llinas R. Is low molecular weight heparin a neuroprotectant? Ann N Y Acad Sci, 1997, 825:389-393.
3Li PA, He QP, Siddiqui MM, et al. Posttreatment with low molecular weight heparin reduces brain edema and infarct volume in rats subjected to thrombotic middle cerebral artery occlusion. Brain Res, 1998, 801(1-2): 220-223.
4Baram D, Rashkovsky M, Hershkoviz R, et al. Inhibitory effects of low molecular weight heparin on mediator release by mast cells: preferential inhibition of cytokine production and mast cell-dependent cutaneous inflammation. Clin Exp Immunol, 1997,110 (3): 485-491.
5Schwartz D, Engelhard D, Gallily R, et al. Glial cells production of inflammatory mediators induced by Streptococcus pneumoniae: inhibition by pentoxifylline, low-molecular-weight heparin and dexamethasone. J Neurol Sci, 1998, 155(1): 13-22.
6Kay R, Wong KS, Yu YL, et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med, 1995, 333(24):1588-1593.
7Bijsterveld NR, Hettiarachchi R, Peters R, et al. Low-molecularweight heparins in venous and arterial thrombotic disease. Thromb Haemost, 1999, 82(suppl 1): 139-147.
8Bath PM, Iddenden R, Bath FJ. Low-molecular-weight heparins and heparinoids in acute ischemic stroke: a meta-analysis of randomized controlled trials. Stroke, 2000,31 (7): 1770-1778.
9Harenberg J, Weuster B, Pfitzer M, et al. Prophylaxis of embolic events in patients with atrial fibrillation using low molecular weight heparin.Semin Thromb Hemost, 1993,19(suppl 1): 116-121.
10Berge E, Abdelnoor M, Makstad PH, et al. Low molecular weight heparin versus aspirin in patients with acute ischemic stroke and atrial fibrillation:a double-blind randomized study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. Lancet, 2000, 355 (9211) : 1205-1210.
